Publications by authors named "Irvine A"

Current diagnosis of urinary tract infections (UTIs) in the UK initially relies on self-reported patient symptoms with no point-of-care test robust enough to accurately identify the causative pathogen and inform on antibiotic susceptibility. In serious UTI cases, standard urine culture is regarded as the gold standard for diagnosis and involves direct isolation, culture and antibiotic susceptibility testing of pathogens. These methods are not suitable in initial UTI diagnosis and treatment because of the time taken to conduct these analyses (≥3 days).

View Article and Find Full Text PDF

In a randomized phase 2b trial (NCT03703102) for adult patients with moderate-to-severe atopic dermatitis (AD), treatment with the T cell rebalancing anti-OX40 receptor antibody rocatinlimab (AMG 451/KHK4083) led to significant improvements in clinical measurements versus placebo including whole-body Eczema Area and Severity Index (EASI) score. AD manifestations can impact variable anatomic regions, and involvement of the head and neck, a sensitive, hard-to-treat area, can negatively impact quality of life. In this post hoc analysis, we investigated response to rocatinlimab treatment across anatomic regions, including the head and neck.

View Article and Find Full Text PDF
Article Synopsis
  • The Measure Up 1, 2, and AD Up studies assessed the effectiveness and side effects of upadacitinib for treating atopic dermatitis in adolescents aged 12-17 over a period of 76 weeks, extending the research beyond the previously available 52-week data.
  • In a randomized clinical trial, participants received either upadacitinib (15 mg or 30 mg) or a placebo, with some receiving topical corticosteroids, allowing for varied analysis of its efficacy and safety.
  • Results showed that a significant percentage of adolescents achieved a major improvement in their condition, with 89.1%, 84.4%, and 87.8% meeting the criteria for reduction in severity, showcasing the medication
View Article and Find Full Text PDF

Automated analysis of flow cytometry data can improve objectivity and reduce analysis time but has generally required work by software and algorithm experts. Here, we investigated the performance of BD ElastiGate™ Software (hereafter ElastiGate), which allows users to automate gating by selecting gated training files, then uses elastic image registration to gate new files. Three assays of increasing complexity were examined: TBNK, stem cell enumeration (SCE), and lymphoid screening tube (LST).

View Article and Find Full Text PDF

Background: The phylum Nematoda is incredibly diverse and includes many parasites of humans, livestock, and plants. Peptide-activated G protein-coupled receptors (GPCRs) are central to the regulation of physiology and numerous behaviors, and they represent appealing pharmacological targets for parasite control. Efforts are ongoing to characterize the functions and define the ligands of nematode GPCRs, with already most peptide GPCRs known or predicted in Caenorhabditis elegans.

View Article and Find Full Text PDF
Article Synopsis
  • Musical training does not seem to enhance the neural processing of sounds, contradicting earlier smaller studies that suggested otherwise.
  • A large-scale study with over 260 participants found no significant correlation between musical training and neural responses to speech sounds.
  • The research indicates a lack of evidence for neural plasticity in early auditory responses tied to musical training and exposure.
View Article and Find Full Text PDF

Background: Tracheostomy, a common procedure performed in intensive care units (ICU), is associated with communication impairment and affects patient well-being. While prior research has focused on physiological care, there is a need to address communication needs and quality of life (QOL). We aimed to evaluate how different types of communication devices affect QOL, speech intelligibility, voice quality, time to significant events, clinical response and tolerance, and healthcare utilization in patients undergoing tracheostomy.

View Article and Find Full Text PDF

Background: Janus kinase inhibitors (JAKi) have the potential to alter the landscape of atopic dermatitis (AD) management dramatically, owing to promising efficacy results from phase III trials and their rapid onset of action. However, JAKi are not without risk, and their use is not appropriate for all patients with AD, making this a medication class that dermatologists should understand and consider when treating patients with moderate-to-severe AD.

Objectives: To provide a consensus expert opinion statement from the International Eczema Council (IEC) that provides a pragmatic approach to prescribing JAKi, including choosing appropriate patients and dosing, clinical and laboratory monitoring and advice about long-term use.

View Article and Find Full Text PDF
Article Synopsis
  • Atopic dermatitis (AD) is a prevalent skin condition that can occur in individuals of any age, and while dupilumab shows promising efficacy as a monoclonal antibody therapy, its use has been linked to a higher occurrence of ocular side effects.
  • The British Association of Dermatologists and the Royal College of Ophthalmologists developed guidance on how to manage these dupilumab-related ocular surface disorders (DROSD) after forming a multidisciplinary group to review literature and recommendations.
  • Key recommendations include that treatment with dupilumab should not be delayed for most eye issues, hydration drops are not advised as preventive measures, and specific guidance is provided for managing DROSD in both children under 7 and those older, with a focus on
View Article and Find Full Text PDF
Article Synopsis
  • - The study focused on atopic dermatitis (AD) and evaluated how much time patients spent with clear skin and minimal itch while being treated with upadacitinib compared to a placebo and dupilumab.
  • - Researchers analyzed data from three phase 3 studies involving nearly 2,400 patients, with treatments lasting from 16 to 24 weeks and assessed using established skin severity and itch scales.
  • - Results showed that patients on upadacitinib experienced significantly more days with better skin conditions and reduced itching compared to those on placebo or dupilumab.
View Article and Find Full Text PDF
Article Synopsis
  • * Key discussions included the prevalence of AD, advancements in treatment and management, and the importance of considering environmental and lifestyle factors affecting patients.
  • * The forum emphasizes the need for increased awareness and collaboration among stakeholders to close the gap between research advancements and practical applications in patient care.
View Article and Find Full Text PDF

Background: Despite the widespread off-label use of methotrexate (MTX) for the treatment of atopic dermatitis (AD), there is limited high-quality evidence on dosing regimens and existing guidelines do not provide clear recommendations regarding dosing strategies.

Objective: The aim of this study was to achieve international consensus among AD experts to standardize the dosing regimen for MTX treatment in adults and children with AD.

Methods: An electronic Delphi (eDelphi) study was conducted from October 2021 to September 2022.

View Article and Find Full Text PDF
Article Synopsis
  • The study compares the real-world effectiveness and safety of three treatments for atopic dermatitis: dupilumab, ciclosporin (CyA), and methotrexate (MTX), using data from the A-STAR register in the UK and Ireland.
  • It involved 488 patients (adults and children) and measured treatment outcomes like the Eczema Area and Severity Index (EASI) and quality of life scales over 12 months.
  • Results showed that dupilumab and CyA led to faster improvements in skin severity scores and overall patient outcomes compared to MTX, indicating dupilumab is an effective option in managing atopic dermatitis.
View Article and Find Full Text PDF
Article Synopsis
  • Loss-of-function mutations in the filaggrin gene (FLG) are the strongest genetic risk factor for atopic dermatitis (AD), with a prevalence of 19.1% in AD patients compared to 5.8% in the general population.
  • A systematic review and meta-analysis analyzed data from 248 studies to assess the geographic and ethnic distribution of these mutations, finding they are more common in populations living farther north of the Equator.
  • Despite a significant association between AD and LoF FLG mutations in the Northern hemisphere, these mutations are less prevalent or absent in some ethnic groups, like Middle Easterners and most Africans, indicating a need for tailored AD management strategies.
View Article and Find Full Text PDF

Background: Detailed and invasive clinical investigations are required to identify the causes of haematuria. Highly unbalanced patient population (predominantly male) and a wide range of potential causes make the ability to correctly classify patients and identify patient-specific biomarkers a major challenge. Studies have shown that it is possible to improve the diagnosis using multi-marker analysis, even in unbalanced datasets, by applying advanced analytical methods.

View Article and Find Full Text PDF
Article Synopsis
  • Staphylococcus aureus (SA) colonizes and harms skin in atopic dermatitis, while Staphylococcus epidermidis (SE) can reduce SA's harmful effects.
  • Researchers created a model called a virtual skin site to explore how SA, SE, and the skin barrier interact in atopic dermatitis, leading to skin damage.
  • The study found that stronger growth inhibition of SA by SE prevented skin damage, suggesting a combination treatment targeting both bacteria may restore healthier skin better than just killing SA alone.
View Article and Find Full Text PDF
Article Synopsis
  • Lebrikizumab, an antibody targeting IL-13, showed effectiveness in treating moderate-to-severe atopic dermatitis (AD) in adolescents during three Phase 3 trials (ADvocate1, ADvocate2, ADhere).
  • The analysis focused on 16-week outcomes from these trials, evaluating both physician and patient-reported improvements in symptoms like itching and sleep loss.
  • Results indicated significant improvements in clinical measures for adolescents receiving lebrikizumab compared to placebo, reinforcing its potential as an effective treatment option for AD.
View Article and Find Full Text PDF

Atopic dermatitis (AD) is an inflammatory skin condition with a childhood prevalence of up to 25%. Microbial dysbiosis is characteristic of AD, with Staphylococcus aureus the most frequent pathogen associated with disease flares and increasingly implicated in disease pathogenesis. Therapeutics to mitigate the effects of S.

View Article and Find Full Text PDF

Background: Chronic spontaneous urticaria (CSU) is a common, debilitating skin disorder characterized by recurring episodes of raised, itchy and sometimes painful wheals lasting longer than 6 weeks. CSU is mediated by mast cells which are absent from peripheral blood. However, lineageCD34CD117FcεRI cells in blood have previously been shown to represent a mast cell precursor.

View Article and Find Full Text PDF

Background: Healthcare access for chronic low back pain is complex and should consider not only the health system, but patient care seeking experiences as well. People who live in rural and remote communities and/or identify as being Indigenous may often encounter additional barriers to accessing care for chronic low back pain; thus, these contexts must be considered to fully understand barriers and facilitators.

Aims: The aim of this study was to understand care-seeking experiences of people living with chronic back pain in Saskatchewan and determine unique experiences facing urban, rural, remote, and/or Indigenous peoples.

View Article and Find Full Text PDF